Fibrosis and inflammation mediators

Fibrosis and inflammation mediators represent a broad functional category of signaling molecules, including cytokines, chemokines, and growth factors, that coordinate the body's response to tissue injury and infection (Medzhitov, 2008, Nature). While essential for normal wound healing and immune defense, chronic activation of these mediators leads to persistent inflammation and excessive deposition of extracellular matrix components, resulting in tissue fibrosis and organ dysfunction (Wynn & Ramalingam, 2012, Nature Medicine). Key players in this group include Transforming growth factor-beta (TGF-beta), Tumor necrosis factor-alpha (TNF-alpha), and various Interleukins (Kendall & Feghali-Bostwick, 2014, Frontiers in Pharmacology). Because this term describes a functional category rather than a single molecular entity, it encompasses a wide array of therapeutic targets across multiple disease states, including idiopathic pulmonary fibrosis, cirrhosis, and chronic kidney disease. Therapeutic strategies often involve neutralizing these mediators or blocking their respective receptors to halt disease progression.

Other names

Pro-inflammatory and pro-fibrotic factorsInflammatory mediatorsFibrogenic cytokinesMediators of chronic inflammation and tissue remodeling

The mechanism of action involves the targeted inhibition of specific pro-inflammatory or pro-fibrotic signaling pathways. This is achieved through various modalities, including the use of monoclonal antibodies to neutralize circulating cytokines, the application of receptor antagonists to block signal transduction, or the use of small molecule inhibitors to target intracellular kinases involved in fibrotic signaling.